I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| enterocyte | 7 studies | 36% ± 3% | |
| epithelial cell | 7 studies | 26% ± 11% | |
| hepatocyte | 5 studies | 52% ± 28% | |
| fibroblast | 3 studies | 37% ± 26% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| enterocyte | 7 studies | 36% ± 3% | |
| epithelial cell | 7 studies | 26% ± 11% | |
| hepatocyte | 5 studies | 52% ± 28% | |
| fibroblast | 3 studies | 37% ± 26% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| intestine | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 4040.54 | 226 / 226 | 97% | 23.60 | 394 / 406 |
| pancreas | 100% | 855.44 | 327 / 328 | 91% | 15.11 | 162 / 178 |
| stomach | 74% | 334.05 | 266 / 359 | 81% | 6.62 | 232 / 286 |
| bladder | 71% | 2583.81 | 15 / 21 | 70% | 10.22 | 351 / 504 |
| intestine | 59% | 1406.54 | 570 / 966 | 76% | 5.71 | 401 / 527 |
| ureter | 0% | 0 | 0 / 0 | 100% | 4.91 | 1 / 1 |
| lung | 69% | 111.44 | 396 / 578 | 31% | 2.44 | 361 / 1155 |
| esophagus | 36% | 69.31 | 516 / 1445 | 57% | 5.69 | 104 / 183 |
| breast | 60% | 411.15 | 274 / 459 | 18% | 0.74 | 196 / 1118 |
| skin | 55% | 126.93 | 993 / 1809 | 2% | 0.09 | 8 / 472 |
| kidney | 27% | 175.44 | 24 / 89 | 15% | 0.55 | 139 / 901 |
| prostate | 40% | 117.39 | 97 / 245 | 3% | 0.04 | 14 / 502 |
| uterus | 3% | 11.79 | 5 / 170 | 30% | 2.17 | 139 / 459 |
| adipose | 19% | 38.31 | 224 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 13% | 0.31 | 10 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 11% | 0.48 | 5 / 45 |
| adrenal gland | 0% | 0.96 | 1 / 258 | 3% | 0.07 | 7 / 230 |
| ovary | 1% | 0.36 | 1 / 180 | 1% | 0.02 | 4 / 430 |
| peripheral blood | 1% | 5.13 | 12 / 929 | 0% | 0 | 0 / 0 |
| heart | 1% | 0.45 | 5 / 861 | 0% | 0 | 0 / 0 |
| spleen | 0% | 2.96 | 1 / 241 | 0% | 0 | 0 / 0 |
| blood vessel | 0% | 0.35 | 5 / 1335 | 0% | 0 | 0 / 0 |
| brain | 0% | 0.13 | 4 / 2642 | 0% | 0 | 0 / 705 |
| muscle | 0% | 0.10 | 1 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| thymus | 0% | 0 | 0 / 653 | 0% | 0 | 0 / 605 |
| GO_0006703 | Biological process | estrogen biosynthetic process |
| GO_0032526 | Biological process | response to retinoic acid |
| GO_0008202 | Biological process | steroid metabolic process |
| GO_0008209 | Biological process | androgen metabolic process |
| GO_0001701 | Biological process | in utero embryonic development |
| GO_0001890 | Biological process | placenta development |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0004303 | Molecular function | estradiol 17-beta-dehydrogenase [NAD(P)+] activity |
| GO_0047006 | Molecular function | 17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity |
| GO_0047035 | Molecular function | testosterone dehydrogenase (NAD+) activity |
| Gene name | HSD17B2 |
| Protein name | Hydroxysteroid 17-beta dehydrogenase 2 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD 2) (20 alpha-hydroxysteroid dehydrogenase) (20-alpha-HSD) (E2DH) (Estradiol 17-beta-dehydrogenase 2) (EC 1.1.1.62) (Microsomal 17-beta-hydroxysteroid dehydrogenase) (Short chain dehydrogenase/reductase family 9C member 2) (Testosterone 17-beta-dehydrogenase) (EC 1.1.1.239) |
| Synonyms | SDR9C2 EDH17B2 |
| Description | FUNCTION: Catalyzes the NAD-dependent oxidation of the highly active 17beta-hydroxysteroids, such as estradiol (E2), testosterone (T), and dihydrotestosterone (DHT), to their less active forms and thus regulates the biological potency of these steroids. Oxidizes estradiol to estrone, testosterone to androstenedione, and dihydrotestosterone to 5alpha-androstan-3,17-dione. Also has 20-alpha-HSD activity. . |
| Accessions | H3BNN1 ENST00000569351.2 H3BQY3 ENST00000568090.5 ENST00000566213.1 ENST00000566838.2 H3BRZ6 H3BV42 H3BS44 ENST00000199936.9 ENST00000563491.5 P37059 |
